Overview

Dapagliflozin Evaluation to Improve the LIVEs of Patients With PReserved Ejection Fraction Heart Failure.

Status:
Active, not recruiting

Trial end date:
2022-01-10

Target enrollment:

Participant gender:

Summary

This is an international, multicentre, parallel-group, event-driven, randomised, double-blind, placebo-controlled study in HFpEF patients, evaluating the effect of dapagliflozin 10 mg versus placebo, given once daily in addition to background regional standard of care therapy, including treatments to control co-morbidities, in reducing the composite of CV death or heart failure events.

Phase:

Phase 3

Details

Lead Sponsor:

AstraZeneca

Treatments:

Dapagliflozin